VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial

Name: Amplia Therapeutics
Address: Level 29, 55 Collins Street, Melbourne, VIC, 3000, Australia

Posted on 07 Apr 2022 . Updated on 07 Apr 2022 by Amplia Therapeutics

In this video, Amplia CEO and MD, Dr John Lambert, explains what's to come in the Phase 2 clinical trial for our Focal Adhesion Kinase (FAK) inhibitor, AMP945, in first-line patients with advanced pancreatic cancer.